WHO WPRO Regional Polio Reference Laboratory and State Key Laboratory for Molecular Virology and Genetic Engineering, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 27, Nanwei Road, Xuanwu District, 100050, Beijing, People's Republic of China.
Arch Virol. 2010 Feb;155(2):197-205. doi: 10.1007/s00705-009-0564-9. Epub 2009 Nov 28.
A type 2 vaccine-related poliovirus (strain CHN3024), differing from the Sabin 2 strain by 0.44% in the VP1 coding region was isolated from a patient with vaccine-associated paralytic poliomyelitis. Sequences downstream of nucleotide position 6735 (3D(pol) coding region) were derived from an unidentified sequence; no close match for a potential parent was found, but it could be classified into a non-polio human enteroviruses species C (HEV-C) phylogeny. The virus differed antigenically from the parental Sabin strain, having an amino acid substitution in the neutralizing antigenic site 1. The similarity between CHN3024 and Sabin 2 sequences suggests that the recombination was recent; this is supported by the estimation that the initiating OPV dose was given only 36-75 days before sampling. The patient's clinical manifestations, intratypic differentiation examination, and whole-genome sequencing showed that this recombinant exhibited characteristics of neurovirulent vaccine-derived polioviruses (VDPV), which may, thus, pose a potential threat to a polio-free world.
从 1 例疫苗相关麻痹性脊髓灰质炎患者中分离到一株与 Sabin 2 株相差 0.44%的 2 型疫苗衍生脊灰病毒(株 CHN3024)。核苷酸位置 6735 下游(3D(pol)编码区)的序列来源于一个未识别的序列;未发现潜在亲本的密切匹配,但可将其归入非脊灰人肠道病毒 C 种(HEV-C)系统发育。该病毒在中和抗原位点 1 发生了氨基酸取代,在抗原性上与亲本 Sabin 株不同。CHN3024 与 Sabin 2 序列的相似性表明重组是近期发生的;这一推测得到了如下数据的支持:OPV 初始剂量是在采样前 36-75 天给予的。患者的临床表现、同型分化检测和全基因组测序表明,该重组病毒具有神经毒力疫苗衍生脊灰病毒(VDPV)的特征,因此可能对无脊灰世界构成潜在威胁。